Human IGF-I/IGF-1 Biotinylated Antibody
Human IGF-I/IGF-1 Biotinylated Antibody Summary
Human IGF-I/IGF-1 Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Insulin-like growth factor I, also known as somatomedin C, is the dominant effector of growth hormone and is structurally homologous to proinsulin. Human IGF-I/IGF-1 is synthesized as two precursor isoforms with N- and alternate C-terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa mature IGF-I/IGF-1 is identical between isoforms and is generated by proteolytic removal of the N- and C-terminal regions. Mature human IGF-I/IGF-1 shares 94% and 96% aa sequence identity with mouse and rat IGF-I/IGF-1, respectively (2), and exhibits cross-species activity. It shares 64% aa sequence identity with mature human IGF-II/IGF-2. Circulating IGF-I/IGF-1 is produced by hepatocytes, while local IGF-I/IGF-1 is produced by many other tissues in which it has paracrine effects (1). IGF-I/IGF-1 induces the proliferation, migration, and differentiation of a wide variety of cell types during development and postnatally (3). IGF-I/IGF-1 regulates glucose and fatty acid metabolism, steroid hormone activity, and cartilage and bone metabolism (4 - 7). It plays an important role in muscle regeneration and tumor progression (1, 8). IGF-I binds IGF-I R, IGF-II R, and the insulin receptor, although its effects are mediated primarily by IGF-I R (9). IGF-I/IGF-1 association with IGF binding proteins increases its plasma half-life and modulates its interactions with receptors (10).
- Philippou, A. et al. (2007) In Vivo 21:45.
- Sandberg-Nordqvist, A.C. et al. (1992) Brain Res. Mol. Brain Res. 12:275.
- Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890.
- Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620.
- Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577.
- Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275.
- Malemud, C.J. (2007) Clin. Chim. Acta 375:10.
- Samani, A.A. et al. (2007) Endocrine Rev. 28:20.
- LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302.
- Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421.
Citations for Human IGF-I/IGF-1 Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 5
Filter your results:
Tough Composite Hydrogels with High Loading and Local Release of Biological Drugs
Authors: J Li, E Weber, S Guth-Gunde, M Schuleit, A Kuttler, C Halleux, N Accart, A Doelemeyer, A Basler, B Tigani, K Wuersch, M Fornaro, M Kneissel, A Stafford, BR Freedman, DJ Mooney
Adv Healthc Mater, 2018;0(0):.
Sample Types: Serum
Applications: ELISA Detection
Calling Biomarkers in Milk Using a Protein Microarray on Your Smartphone.
Authors: Ludwig S, Tokarski C, Lang S, van Ginkel L, Zhu H, Ozcan A, Nielen M
PLoS ONE, 2015;10(8):e0134360.
Sample Types: Milk
Applications: Array Development
ATM regulates insulin-like growth factor 1-secretory clusterin (IGF-1-sCLU) expression that protects cells against senescence.
Authors: Luo X, Suzuki M, Ghandhi S, Amundson S, Boothman D
PLoS ONE, 2014;9(6):e99983.
Sample Types: Cell Culture Supernates
Applications: ELISA Development (Detection)
Development and validation of sandwich ELISA microarrays with minimal assay interference.
Authors: Gonzalez RM, Seurynck-Servoss SL, Crowley SA
J. Proteome Res., 2008;7(6):2406-14.
Sample Types: Serum
Applications: ELISA Microarray Development
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
Authors: Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A
Clin. Cancer Res., 2007;13(3):1000-9.
Sample Types: Plasma
Applications: ELISA Development
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Supplemental Cell Selection Products
Supplemental ELISA Products
Reviews for Human IGF-I/IGF-1 Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Human IGF-I/IGF-1 Biotinylated Antibody and earn rewards!
Have you used Human IGF-I/IGF-1 Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image